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The purpose of this study was to determine the role of the retinol dehydrogenase 12 (RDH12) gene in patients aﬀected with Leber
congenital amaurosis (LCA), autosomal recessive retinitis pigmentosa (arRP) and autosomal dominant/recessive cone-rod dystrophies
(CORD). Changes in the promoter region, coding regions and exon/intron junctions of the RDH12 gene were evaluated using direct
DNA sequencing of patients aﬀected with LCA (n = 36 cases), RP (n = 62) and CORD (n = 21). The allele frequency of changes
observed was assessed in a multiethnic control population (n = 159 individuals). Detailed biochemical and structural modeling analysis
of the observed mutations were performed to assess their biological role in the inactivation of Rdh12. A comprehensive clinical assess-
ment of retinal structure and function in LCA patients carrying mutations in the RDH12 gene was completed. Of the six changes iden-
tiﬁed, three were novel including a homozygous C201R change in a patient aﬀected with LCA, a heterozygous A177V change in patients
aﬀected with CORD and a heterozygous G46G change in a patient aﬀected with LCA. A novel compound heterozygote T49M/
A269fsX270 mutation was also found in a patient with LCA, and both homozygous and heterozygous R161Q changes were seen in
26 patients aﬀected with LCA, CORD or RP. These R161Q, G46G and the A177V sequence changes were shown to be polymorphic.
We found that Rdh12 mutant proteins associated with LCA were inactive or displayed only residual activity when expressed in COS-7
and Sf9 cells, whereas those mutants that were considered polymorphisms were fully active. Thus, impairment of retinal structure and
function for patients carrying these mutations correlated with the biochemical properties of the mutants.
 2007 Elsevier Ltd. All rights reserved.
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Leber congenital amaurosis (LCA)1 is an autosomal
recessive, early onset severe retinal dystrophy and a leading
cause of inherited childhood blindness. It accounts for 5%0042-6989/$ - see front matter  2007 Elsevier Ltd. All rights reserved.
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E-mail addresses: eheon@attglobal.net (E. He´on), kxp65@case.edu (K. Pa
1 Abbreviations used: Ar, autosomal recessive; CORD, cone-rod dystrophy; G
morpholino)ethane-sulfonic acid; FD-OCT, Fourier-domain optical coherence
visual acuity.of all inherited retinal dystrophies (Cremers, van den Hurk,
& den Hollander, 2002; Hanein et al., 2004; Perrault et al.,
1999; Weleber, 2002). Mutations in eleven genes have been
identiﬁed which together account for 55% of LCA cases.
These genes encode proteins involved in phototransduc-n Sciences, The Hospital for Sick Children, University of Toronto, Canada
lczewski).
VF, Goldmann visual ﬁeld; LCA, leber congenital amaurosis; MES, 2-(N-
tomography; RDH, retinol dehydrogenase; RP, retinitis pigmentosa; VA,
2056 W. Sun et al. / Vision Research 47 (2007) 2055–2066tion, transcription, metabolic pathways, and other pro-
cesses aﬀecting retinal function. Mutations in genes which
have been shown to cause LCA or related early-onset
severe retinal dystrophies include CRX (Cone-Rod
Homeobox) (Sohocki et al., 1998; Swaroop et al., 1999),
CRB1 (Crumbs Homolog 1) (Cremers et al., 2002), AIPL1
(Aryl-hydrocarbon-interacting protein like 1) (Sohocki
et al., 2000; Sohocki, Perrault et al., 2000), GUCY2D
(Guanylate Cyclase E) (Perrault et al., 1996), TULP1
(Tubby-like protein 1) (Hanein et al., 2004), RPGRIP1
(Retinitis Pigmentosa GTPase Regulator Interaction Pro-
tein 1) (Cremers et al., 2002), IMPDH1 (inosine mono-
phosphate dehydrogenase type I) (Bowne et al., 2006),
RDH12 (retinol dehydrogenase 12) (Janecke et al., 2004;
Perrault et al., 2004; Thompson et al., 2005), RPE65 (Ret-
inal Pigment epithelium protein with molecular mass 65
kDa) (Gu et al., 1997; Morimura et al., 1998), LRAT (lec-
ithin:retinol acyltransferase) (Thompson et al., 2001), RD3
(retinal degeneration 3) (Friedman et al., 2006), and
CEP290 (a centrosomal protein) (den Hollander et al.,
2006).
Janecke et al., identiﬁed ﬁve mutations in the RDH12
gene in patients aﬀected by LCA (Janecke et al., 2004).
The retinal structure of patients with RDH12 mutations
was appreciably distorted, precluding identiﬁcation of nor-
mal laminae (Jacobson et al., 2007). Subsequent studies
have identiﬁed additional novel mutations in the RDH12
gene associated with early onset cone-rod dystrophy
(CORD) and LCA (Perrault et al., 2004; ThompsonH151D/N
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Fig. 1. Intron/exon gene structure of human RDH12 and all identiﬁed genetic v
other to cover the entire RDH12 gene. For comparison, genetic variants identiﬁ
below the structure. New genetic variants found in this study are denoted witet al., 2005) (Fig. 1). The RDH12 gene (chromosome
14q24) is approximately 12 kb in length (Haeseleer et al.,
2002), consisting of seven exons (Fig. 1). The highest
expression level of RDH12 is observed in the retina (Haese-
leer et al., 2002). Rdh12 is a member of the short-chain
dehydrogenase/reductase (SDR) family (Jornvall et al.,
1995) and belongs to a sub-family of dual-speciﬁcity retinol
dehydrogenases that metabolize both all-trans and cis-reti-
nols/retinals (Haeseleer et al., 2002). Rdh12 is also involved
in the metabolism of other non-retinoid alcohols/aldehydes
(Belyaeva et al., 2005). In photoreceptor cells Rdh12 local-
izes to the inner segment of rod and cone photoreceptors
(Haeseleer et al., 2002; Kurth et al., 2007; Maeda et al.,
2006). Deletion of this gene in mice increased susceptibility
to light-induced photoreceptor apoptosis (Maeda et al.,
2006). Hence, we have speculated that light damage con-
tributes to the severe visual impairment of individuals with
null mutations in the RDH12 gene.
To further assess the role of Rdh12 in retinal dystro-
phies, genomic DNA from 119 patients (LCA, RP, and
CORD) were collected and analyzed for mutations of the
coding sequences, intron/exon junction regions and pro-
moter region using direct sequencing. Six diﬀerent variants
were observed of which three variants were novel. Detailed
biochemical analyses were carried out on ﬁve of these vari-
ants to assess their biological implication in the inactiva-
tion of Rdh12. Comprehensive clinical examination of
patients carrying these mutations provides further insight
into the underlying mechanisms of visual impairment.STOP
(Thompson et al., 2005)
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2.1. Patient data collection
Patient information and DNA samples were collected respecting the
regulation of the Health Information Portability and Accountability Act
(HIPAA), the policies of Institutional Review Board of Case Western
Reserve University, Cleveland, USA and that of the Research Ethics
Board of Hospital for Sick Children, Toronto, Canada. This project
respected the tenets of the Declaration of Helsinki. Consent and/or assent
forms were obtained from all participants. Comprehensive eye examina-
tion included full ﬁeld electroretinography (ERG) recorded according to
the ISCEV standard (Marmor, Holder, Seeliger, & Yamamoto, 2004)
and Goldmann visual ﬁeld (GVF) testing. A Fourier-domain high-speed
high–resolution OCT system (axial resolution was 4.5 lm; acquisition
speed was 10,000 A – scans/frame, 9 frames/second) constructed at the
UC Davis Medical Center combined with a hand-held scanner (Bioptigen,
Inc.) was used for retinal layer image acquisition (Zawadzki et al., 2005).
A total of 119 patients were included and carried the clinical diagnoses of
either LCA (36 cases), arRP onset (62 cases) or CORD (21 cases). The
exclusion criteria were the following: (1) non-availability of clinical infor-
mation; (2) follow up was not possible; and (3) the nature of the retinal dis-
ease appeared not to be genetically determined. Genomic DNA from
patient blood samples were extracted and puriﬁed using standard protocols.
2.2. Mutation screening
According to the RDH12 gene sequence, primer pairs were designed to
generate three overlapping PCR fragments (Fig. 1). PCR was performed
according to manufacturer’s suggestion (TripleMaster system, Eppendorf)
and products were analyzed on a 0.8% agarose gel to verify production of
a single band of expected length. Sequencing was performed utilizing
primers designed for each exon, intron–exon junction region and the pro-
moter region. Primer sequences for PCR and sequencing are included in
Tables 1 and 2. Sequencing was performed on ABI 3730xl and all data
were analyzed with Finch TV (www.geospiza.com/ﬁnchtv/) and BioEdit
7.0.5.3 (www.mbio.ncsu.edu/BioEdit/bioedit.html) software.
2.3. Mutagenesis
Human RDH12 cDNA (Reference sequence is NM_152443 in NCBI
database but G482 allele) was provided by Dr. F. Haeseleer (Depart-
ment of Ophthalmology, University of Washington). Constructs were
generated by using the QuickChange site-directed mutagenesis kitTable 1
Sequences of primers used in the experiments
Name Sequence 5 0–3 0 Fa
5hRDH12-1 TCTCTGTGACTTATGCCTATATCTGTCC
p
3hRDH12-2 CAGCAAATGTGTACTAACTACCGACTCT
5hRDH12-4 CCCAAGCTCACTTACTATACCTCCTTTA
p
3hRDH12-4 CTATAGGTTGAGCATCCCTTATCAGAA
5hRDH12-5 AATGAGCAACTAGAGTCTGGGAGTAAAG
p
3hRDH12-7 GACACTACAGAGAGGTGAGATGTAGC
f6-2 TTCCATCTTTGCAGTAGAGGTGG
p
r2 TCCTGGGTGCTGAGCAGCAGC
f11-3 CTAAAAGGAGATACTAAGTGACAT
p
r1 CACAGTAGTACTGTTCAGTCTTC
f13-2 CCCAGTGACAATGCTTATTGG
p
f15-2 GAGGAATCCACAAACTCAGACC
p
f20 TGAAATAGAAGGACCTCCGAACC
p
f29-2 TTAGACCTGGTACTAGATCTTG
p
f30-2 GCCAGCTGGTGCTGCGAATCC
p
a F, forward.
b R, reverse.(Stratagene, La Jolla, CA). The RDH12 cDNA was subcloned into
pcDNA3.1 and mutations corresponding to those identiﬁed in this
study were introduced and conﬁrmed by DNA sequencing. To eliminate
the possibility of generating mutations in the vector sequence during
mutagenesis, cDNA inserts were cut out with restriction enzymes and
ligated into pcDNA3.1 (Invitrogen, Carlsbad, CA) for COS-7 cell
expression and pFastBac HT (Invitrogen, Carlsbad, CA) for Sf9 cells
expression. To produce baculovirus, pFastBac HT vector with inserts
were transformed into DH10Bac competent cells. Positive clones were
selected and PCR analyzed. Puriﬁed Bacmid was used for transfecting
Sf9 cells and supernatant was collected as virus stock. Viral titer was
determined via plaque assay.2.4. Rdh12 expression and activity assay
Wild-type and mutant constructs of Rdh12 were transiently expressed
in COS-7 cells and Sf9 cells. Fugene 6 (Roche Applied Science, Indianap-
olis, IN) was used for transfection (3 ll of reagent/1 lg of DNA per well of
a 6-well plate) according to manufacturer’s instructions. Cells were col-
lected two days post transfection and stored at 20 C in storage buﬀer
(140 mM NaCl, 3 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4, and pH
7.4, containing 1% BSA and 20% glycerol). Baculovirus infection was per-
formed according to manufacturer’s instructions (Invitrogen, Carlsbad,
CA). In each 35 mm well, 2 · 106 cells were seeded and one hour later were
infected with baculovirus at a multiplicity of infection (MOI) of 0.1–0.5.
Sf9 cells were collected three days post-infection by centrifugation and
stored at 20 C in storage buﬀer. Protein was boiled and centrifuged
before SDS–PAGE analysis.
Rdh12 activity assays were performed as previously described (Jang
et al., 2001; Jang, McBee, Alekseev, Haeseleer, & Palczewski, 2000;
Jang, Van Hooser et al., 2001). In brief, the reaction mixture contained
cell lysate in 50 mM MES, pH 5.5, containing 1.2 mM NADPH, 20 lM
all-trans-retinal, 0.1% Triton X-100, 0.5% bovine serum albumin (BSA)
and 10% glycerol. The reaction was quenched by the addition of 300 ll
ice-cold methanol 30 min after incubation at 37 C. Following the addi-
tion of methanol, 300 ll of hexane was added to extract retinoids. Ret-
inoids were separated by normal phase HPLC (Ultrasphere-Si, 4.6 l
250 mm, Beckman, Fullerton, CA). The hexane solution was analyzed
by HPLC using 10% ethyl acetate in hexane and monitored at
325 nm to conﬁrm the production of retinol. Km and Vmax were derived
from a plot of the inverse of the initial velocity of all-trans-retinol for-
mation at six substrate concentrations and the inverse of the all-trans-
retinal concentration. Reaction conditions were same as above, but
were performed for 8 min at 37 C.Rb Location Usage
Promoter region Amplify PCR fragment a (Fig. 1)p
Intron 3 Amplify PCR fragment a (Fig. 1)
Intron 2 Amplify PCR fragment b (Fig. 1)p
Intron 6 Amplify PCR fragment b (Fig. 1)
Intron 6 Amplify PCR fragment c (Fig. 1)p
After exon 7 Amplify PCR fragment c (Fig. 1)
Promoter region Sequencingp
Exon 1 Sequencing
Intron 2 Sequencingp
Intron 2 Sequencing
Intron 3 Sequencing
Intron 4 Sequencing
Intron 5 Sequencing
Intron 6 Sequencing
Exon 7 Sequencing
Table 2
Primers for control population screening
Mutations screened Primer sequence Product size (bp) MgCl2 (mM) Tm (C) Cycles Other
Exon 2 (G46G/T49M) CCGATAAACAGGCGACTACCTT 400 1.0 66 35 Q solution
TGGAAACACAAAGCAATATGGACA
Exon 5 C201R (binds to mutant T) TGTTGCAAAAAGCTACTGTGA 347 1.0 57 39
AGCAGGGGTTTTGCCGATC
Exon 5 A177V TGTTGCAAAAAGCTACTGTGA 223 1.0 54 51
GTTAATGTGTTCTCGGTAGT
Exon 5 R160Q AATTGGTTCACACCCAGAAGA 398 1.0 66 35
TGACTTCCCAAGTTCCTGTG
Exon 5 for sequencing TGTTGCAAAAAGCTACTGTGA 594 1.0 57 39
AATTGGTTCACACCCAGAAGA
Exon 6 c.806delCCCTG CTTCTCCCCCTTTGTCAAGA 199 1.0 56 38
TCATCAGGCACAAACTCAGC
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3.1. Patient recruitment and mutational analysis
One hundred nineteen patients of various ages were
enrolled in this study (details in section 2, Table 3). Six
variants (three novel) were identiﬁed in these patients
aﬄicted with either LCA, arRP or CORD by direct
sequencing of the RDH12 exon, intron–exon junctions
and promoter regions (Table 3). Variants identiﬁed were
located within the coding region and not in splice junctions
or the promoter regions (Fig. 1). The three novel variants
identiﬁed were: (1) a heterozygous 138C! T mutation,
which is a silent mutation in exon 2 leaving Gly unchanged
at amino acid position 46; (2) a heterozygous 530C! T
mutation in exon 5 that changes Ala177 to Val; (3) homozy-
gote 601T! C mutation in exon 5 that changes residue
Cys201 to Arg. We also identiﬁed a novel compound hetero-
zygote T49M/A269fsX270 in a patient with LCA. Other
variants seen included the 146C! T mutation (T49M,
exon 2); 482G! A mutation (R161Q, exon 5); 806del-
Table 3
Mutations in the coding region of RDH12
Location Nucleotide changea Change in amino acid residue
Heterozygote
Exon 2 138C! T (new) G46Ge
Exon 5 530C! T (new) A177V
Compound heterozygote
Exon 2 146C! T T49M
Exon 6 806delCCCTG A269fsX270 (missing C-terminal 4
Hetero- and homo-zygote
Exon 5 482G! A R161Q
Homozygote
Exon 5 601T! C (new) C201R
Total patient number
119
a Nucleotides are numbered from the ﬁrst base of the start (ATG) codon. Ref
nucleotide 482 in the reference sequence to a G. G482 allelle).
b LCA, Leber congenital amaurosis.
c arRP, autosomal recessive retinitis pigmentosa.
d CORD, cone-rod dystrophy.
e This mutation does not appear to generate an amino acid substitution, but it
alternatively spliced and likely truncated protein.CCCTG mutation (A269fsX270, exon 6); as well as the
R161Q variant assumed to be a polymorphism (Thompson
et al., 2005).
3.2. Impact of mutations on the Rdh12 structure
The mutations and polymorphisms found in this study
(Table 3) comprise several diﬀerent ‘‘classes’’ of mutations
(Fig. 2). These mutations result in altered function due to
defects in the substrate- or co-factor-binding site, whereas
others can directly interfere with the catalysis of the reac-
tion through disruption of the active site. The G46G silent
mutation which on ﬁrst glance appears to be a silent muta-
tion, can lead to the generation of an altered splice acceptor
site (sequence analyzed by ESE ﬁnder software, http://
rulai.cshl.edu/tools/ESE/), resulting in the production of
a truncated or malformed protein. The T49M mutation
would likely interfere with the binding of NADP, as this
residue is located in the phosphate-binding loop and the
larger, more hydrophobic side chain of Met could perturb
co-factor binding (Figs. 2 and 3). The R161Q polymor-Number of patients LCAb arRPc CORDd
1 1
2 2
1 (Patient 1) 1
7aa)
26 7 13 6
1 (Patient 2) 1
LCA arRP CORD
36 62 21
erence sequence is NM_152443 in NCBI database (with a change from A at
may result in the generation of an alternate splice acceptor site, yielding an
                                        50                                               100
hRDH12  MLVTLGLLTSF---FSFLYMVAPSIRKFFAGGVCRTNVQLPGKVVVITGANTGIGKETARELASRGARVYIACRDVLKGESAASEIRVDTKNSQVLVRKL
bRDH12  MLVVLGLLTSF---LSFLYVIAPSIRKFFAGGVCRTDVQLFGKVVVITGANTGIGKETARELARRGARVYIACRDVLKGESAASEIQADTKNSQVLVRKL
mRDH12  MLFILVLLTSF---LSILYLTAPSIRKFFAGGVCTTNVQIPGKVVVITGANTGIGKETARELARRGARVYIACRDVLKGESAASEIRADTKNSQVLVRKL
dRDH12  MLALVAFAAGLGLVALILRLLSPQIRKYAAGGSCRSTVRLDGKVALVTGANSGIGKETALDLASRGARVILACRDLEKAEEAAAEIRTRVGGAKVEVREL
     G -----G—G    
                                                       150                                               200
hRDH12  DLSDTKSIRAFAEGFLAEEKQLHILINNAGVMMCPYSKTADGFETHLGVNHLGHFLLTYLLLEQLKVSAPARVVNVSSVAHHIGKIPFHDLQSEKRYSRG
bRDH12  DLSDTKSIRAFAEGFLAEEKQLHILINNAGVMLCPYSKTADGFETHLAVNHLGHFLLTHLLLGRLKESAPARVVNLSSVAHHLGKIRFHDLQGDKYYNLG
mRDH12  DLSDTKSIRAFAERFLAEEKKLHILINNAGVMMCPYSKTTDGFETHFGVNHLGHFLLTYLLLERLKESAPARVVNLSSIAHLIGKIRFHDLQGQKRYCSA
dRDH12  DLADCCSIRAFAQRFLREVDHLHILINNAGVMMCPYMKTADGFEMQIGVNHLGHYLLTYLLIGLLKRSAPSRIVVVSSLAHNFGWIRFHDLHSQGSYNSG
       250                                               300
hRDH12  FAYCHSKLANVLFTRELAKRLQGTGVTTYAVHPGVVRSELVRHSSLLCLLWRLFSPFVKTAREGAQTSLHCALAEGLEPLSGKYFSDCKRTWVSPRARNN
bRDH12  FAYCHSKLANVLFTRELAKRLKGTGVTTYAVHPGIVRSKLVRHSFLLCLLWRLFSPFLKTTWEGAQTSLHCALAEGLEPLSGKYFSDCKKTWVSPRARNN
mRDH12  FAYGHSKLANLLFTRELAKRLQGTGVTAYAVHPGVVLSEITRNSYLLCLLWRLFSPFFKSTSQGAQTSLHCALAEDLEPLSGKYFSDCKRMWVSSRARNK
dRDH12  LAYCQSKLANVLFTRELARRLQGSNVTVNSVHPGTVRSELVRHSTLMSLLFAFFSMFLKSPKEGAQTSIYCAVAEELQSISGKHFSDCAPAFVAPQGRSE
         Y---K 
hRDH12  KTAERLWNVSCELLGIRWE  
bRDH12  KTAERLWNVSCELLGIRWE  
mRDH12  KTAERLWNVSCELLGIQWE  
dRDH12  ETARKLWDVSCELLGIEWD  
phosphate-binding looptransmembrane domain 
catalytic residues 
G   M 
R  V 
R  
Rossmann fold
Rossmann fold
truncate
Patient 2, homozygote 601T>C
control
Patient 1, compound heterozygote
146C>T
806delCCCTG
Fig. 2. Homology of Rdh12 among diﬀerent species. Rdh12 from human, bovine, mouse and Drosophila are aligned together here to show the sequence
homology. The putative transmembrane domain is located at the N-terminus. Regions corresponding to the Rossmann fold, phosphate-binding site and
catalytic site are also labeled. Polymorphisms/mutations identiﬁed in this study are also indicated. The chromatogram ﬁgures show compound
heterozygote of 146C ! T/806delCCCTG (patient 1) and homozygote of 601T ! C (patient 2).
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binding sites or residues involved in the formation of the
structure of the Rossmann fold, and thus unlikely to be
able to inﬂuence the catalysis of Rdh12. The A177V muta-
tion could disrupt the ability of the enzyme to bind sub-
strate (retinal) as this residue is located in the putative
retinol-binding site. The reason for the altered activity in
the C201R mutant is based on its proximity to and likely
disruption of the catalytic site. The location of the residue
201 is inside the catalytic motif (YXXXK), immediately
after the Tyr residue (Fig. 2). Furthermore, the oligomeric
state of SDR enzymes varies from tetramer to dimer to
monomer and this residue is located in a region that at least
in several other SDRs can be involved in oligomer forma-
tion (Jornvall et al., 1995).
3.3. Impact of mutations on Rdh12 enzymatic activity
To test the enzymatic activity of the Rdh12 variants
found in this study, site directed mutagenesis was used to
create mutant constructs which were cloned intopcDNA3.1 and pFastBac HTa vectors, respectively. Total
cell lysate was obtained two days after transient transfec-
tion in COS-7 cells or three days after virus infection in
Sf9 cells. Immunoblotting with an anti-Rdh12 antibody
(Maeda et al., 2006) conﬁrmed protein expression of
Rdh12 and its mutants. In COS-7 cells, C201R and
A269fsX270 expression levels were not detectable, whereas
other constructs showed polypeptides on SDS–PAGE of
the predicted molecular weight of 38 kDa (data not
shown). In Sf9 cells, expression levels of all mutant con-
structs were comparable to that of the wild-type with the
exception of the C201R construct, which was expressed
at 30% of the wild type (Fig. 4A).
Testing of Rdh12 activity in COS-7 cells, showed a dra-
matic reduction in the ability to produce all-trans-retinol
from all-trans-retinal (95% less) for the T49M
(17.8 pmol), C201R (0 pmol) and A269fsX270 (0 pmol)
variants. The A177V (147.9 pmol) variant had similar pro-
duction of all-trans-retinol compared to wild-type RDH12
(151.0 pmol) (Fig. 5). The R161Q ( 170.4 pmol) variant
which we have putatively classiﬁed as a polymorphism also
Fig. 3. Homology model of Rdh12 showing sites of mutations/polymor-
phisms identiﬁed in this study. Residues 49, 161, 177, and 201 are shown.
The T49M mutation can interfere with NADP binding, whereas change
A177V may interfere with substrate binding. That the R161Q mutation
does not appear to exhibit any changes in enzymatic activity is
unsurprising, because the location is far from the active site and is likely
not involved in catalysis. C201R, which lies close to the catalytic residues,
can disrupt the formation of the active site, leading to a loss of enzymatic
activity. The homology model was built using b-ketoacyl-[ACP]-reductase
from Escherichia coli as a backbone model (PDB ID:1Q7B), using the
Geno3D server (Combet et al., 2002) and O (Jones et al., 1991) for
generation of an initial homology model and manual model building
respectively. Figure was created with PYMOL (DeLano, W.L. The
PyMOL Molecular Graphics System (2002) DeLano Scientiﬁc, San
Carlos, CA, USA. http://www.pymol.org).
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RDH12 wild-type (R161) 24.8 1.3
T49M ND ND
R161Q 25.7 0.7
A177V 19.1 0.8
C201R ND ND
A269fsX270 ND ND
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Fig. 4. (A) Expression of Rdh12 and its mutants. Lanes were loaded with
extracts from Sf9 cells infected with virus only, virus containing RDH12,
T49M, R161Q, A177V, C201R, and A269fsX270 from left to right,
respectively. Immunoblotting was carried out according to standard
protocols using Immobilon-P to adsorb proteins (polyvinylidene diﬂuo-
ride; Millipore Corp.) (Ohguro et al., 1993). Mouse polyclonal antibodies
against bacterially expressed full-length mouse Rdh12 were raised in
BALB/c mice as described previously (Maeda et al., 2006). Secondary
antibody is HRP conjugated anti-mouse IgG (Promega Corporation,
Madison, WI) and signal was detected using SuperSignal West Pico
Chemiluminescent Substrate (Pierce Biotechnology, Rockford, IL). (B)
Calculated Km and Vmax values of Rdh12 constructs expressed in Sf9 cells.
ND, not determined.
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RDH12 as described in previous studies (Janecke et al.,
2004; Perrault et al., 2004). The amount of all-trans-retinol
production was calculated by subtracting background of
membranes isolated from cell transfected with the empty
vector from raw data. Further characterization was carried
out with proteins expressed in Sf9 cells. Proﬁles of the
activity observed in Sf9 cells infected with virus carrying
RDH12 and mutants was similar to that of COS-7 cells
(Fig. 6). Comparable amounts of all-trans-retinol produc-
tion was detected in the wild-type Rdh12 (27.2 pmol),
R161Q mutant (19.2 pmol) and A177V mutant
(17.9 pmol). Almost no production from all-trans-retinal
to retinol was obtained from T49M (0.9 pmol), C201R
(0 pmol) and A269fsX270 (0 pmol) mutants. Again, the
production amount here was calculated by subtractingbackground (empty virus) from raw data. The Km and
Vmax values were determined using proteins expressed in
Sf9 cells. Km for the wild-type Rdh12, R161Q and A177V
mutants were 24.8, 25.7, and 19.1 lM, respectively. Vmax
for these proteins was 1.3, 0.7, and 0.8 pmol/min respec-
tively (Fig. 4B).3.4. Clinical manifestation of RDH12 sequence changes
The genotype–phenotype correlation was evaluated in
two available patients with LCA (Table 4). The compound
heterozygote mutation (T49M/A269fsX270) was identiﬁed
in patient 1 who was from non-consanguineous parents of
Italian ancestry with no known family history of eye dis-
eases. We followed this patient from 6 to 21 years of age.
Abnormal night vision and restricted side vision were ﬁrst
noticed at 2 years of age according to the parents. Visual
acuity (VA) was reduced to 1.0 and 1.3 logarithm of the
minimum angle of resolution (logMAR) with a small
refractive error of +1.25 D (right eye) and +1.0 (left eye)
at 6 years of age. At this age, his fundus had a diﬀuse ret-
inopathy with pigment clumping and bone spiculae pig-
mentation, cystoid macular edema and attenuated blood
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Fig. 5. HPLC analysis of the enzymatic activity of Rdh12 variants in COS-7 cells. Enzyme activity was detected by monitoring all-trans-retinol production
via normal phase HPLC.
W. Sun et al. / Vision Research 47 (2007) 2055–2066 2061vessels with mild optic atrophy in both eyes. Vision was
stable at a second visit 9 years later. Goldmann visual ﬁeld
(GVF) testing revealed constricted ﬁelds to about 5 in
diameter in both eyes with a thin peripheral almost circum-
ferential island in his right eye. ERG was not recordable
above noise for all tested stimuli at 15 years of age. VA
improved slightly to 0.7 logMAR using both eyes, under
oral treatment with carbonic anhydrase inhibitor for the
management of his macular edema, even though he lost
the remaining peripheral ﬁeld. Horizontal and vertical nys-
tagmus was ﬁrst documented at 19 years of age. VA was
stable at his last visit at 21 years of age (Table 4). Fundus
exam revealed atrophic macular changes, optic atrophy
and bone spiculae pigmentation in both eyes at 21 years
of age (Fig. 7).
The novel homozygous 601 T! C mutation (C201R) in
exon 5 was seen in a single patient (patient 2) with LCA.
This change was not seen in 318 control chromosomes.
Patient 2 of Indian ancestry from a consanguineous family
was ﬁrst diagnosed with LCA at 5 years of age. He
reported that he always had nyctalopia and restricted
visual ﬁelds but was able to read printed text at a younger
age. His VA and color perception had signiﬁcantly
deteriorated from 25 years of age. Cataract surgery wasperformed on both eyes at 30 years of age. At this age,
he was only able to notice hand motion in both eyes, which
is equivalent to 2.3 logMAR (Schulze-Bonsel, Feltgen,
Burau, Hansen, & Bach, 2006) (Table 4). Dilated fundus
examination revealed a macular pseudo-coloboma with
dense pigmentation, optic atrophy, arteriole and venous
attenuation and peripheral granular pigmentation in the
both eyes. Horizontal FD-OCT scans through the fovea
revealed a thinned retina with re-organization of the retinal
lamination. Structures of photoreceptors are not identiﬁ-
able. Epiretinal membrane with moderate traction is visible
in the scan through the left foveal region (Fig. 7).
4. Discussion
4.1. Rdh12 inactivation and polymorphisms
Among the ﬁve single missense mutations in the RDH12
gene identiﬁed in this study, the T49M and C201R muta-
tions were catalytically inactive supporting their biological
role in visual impairment. The T49M mutation was previ-
ously reported as a modiﬁer (Thompson et al., 2005) with
increased activity when combined with R161Q polymor-
phism. Four combinations of T49/R161, M49/R161,
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Fig. 6. HPLC analysis of the enzymatic activity of Rdh12 variants in Sf9 cells. The reaction was carried out as described for the COS-7 cells.
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Thompson et al. (2005), M49 showed 1.5  2 fold increase
in reductase activity compared to T49 in either R161 or
Q161 background. To the contrary, our ﬁnding showed
that the T49M change on the R161 background did not
display increased Rdh12 activity as published previously,
but severely decreased RDH activity in both COS-7 and
Sf9 cells (95%). Our results are consistent with the clinical
phenotype and the structural model of the enzyme (Figs. 2
and 3), which predicts that the larger Met residues will
interfere with the binding of the 2 0-phosphate group of
NADP. The diﬀerences in activity of T49M mutant
observed between our study and previous work could be
due in part to diﬀerences in methodology for determining
enzymatic activity.
As expected, the frameshift mutation A269fsX270
resulted in the formation of a truncated nonfunctional pro-
tein, because of the loss of the residues needed to form a
seventh b-strand next to canonical sixth b-strand in the
Rossmann fold is defective in enzymatic activity (Buehner,
Ford, Moras, Olsen, & Rossmann, 1974) (Fig. 3). The
C201R variant is also a loss of function mutation. TheCys residue is located within the catalytic motif (YXXXK),
just after the catalytically important Tyr. The change from
a neutral nonpolar residue to a basic polar residue within
the catalytic motif can disrupt the proper alignment of res-
idues involved in catalysis.
For the R161Q mutant, the amino acid change did not
interfere with the Rdh12 activity because the location of
the residue in the structure is far from the phosphate-bind-
ing site, catalytic site and substrate binding site (Figs. 2 and
3). Allele frequency from control population (12.5%) com-
pared to allele frequency in patients (12.2%) further sup-
port the polymorphic nature of this variant. The A177V
variant did also not alter enzyme activity, which did not
support our prediction that it would alter activity consider-
ing that the location of the residue is in the putative retinol-
binding site. The amino acid residues Ala and Val are very
similar and the change only caused an alkyl extension of
the side chain increasing hydrophobicity within the binding
of hydrophobic second substrate. Furthermore, the residue
may not be in direct contact with the retinol, which would
also explain the apparent lack of eﬀect on enzymatic
activity.
Table 4
Clinical phenotype of patients with RDH12 mutations
Patient
No.
Sex Mutation Age at
test
(years)
Nyctalopia Photophobia Nystagmus Visual
acuity
(logMAR)a
Goldmann
visual ﬁeld
(III4e)b
ERGc
1 M Exon 2: 146C! T; T49M exon 6:
806delCCCTG; A269fsX270; compound
heterozygote
6 +  1.0 / 1.3 NTd NRe
15 +  0.7/1.0 5/5
17 +  0.7/0.7 5/3 (plus
peripheral
island)
19 +  + 0.7/0.7
21 +  + 0.7/0.7
2 M Exon 5: 601T! C; C201R; homozygote 29 +   2.3 /2.3 10/3 NT
32 +   2.3/ 2.3
a LogMAR, logarithm of the minimum angle of resolution. Showed as right eye/left eye.
b Stimulus sizes of III4e (10,000 apostilbs, 0 decibels, 4 mm2).
c ERG, electroretinography.
d NT, not tested.
e NR, non-recordable above noise.
Fig. 7. Fundus photography. A (right eye) and B (left eye) are fundus photography of patient 1 (21 years), with compound mutations (T49M/A269fsX270)
and a LCA phenotype shows diﬀuse retinopathy with pigment clumping and bone spicule pigmentation, cystoid macular edema, attenuated blood vessels
with mild optic atrophy in both eyes. C is fundus photography and corresponding FD-OCT images of patient 2 (32 years) who is homozygous for the
C201R mutation and has a LCA phenotype. Lines are symbolizing area of FD-OCT scan acquisition. Both eyes show a macular pseudo-coloboma with
dense pigmentation, optic atrophy, arteriole and venous attenuation and peripheral granular pigmentation. Foveal and extrafoveal FD-OCT images a–c
demonstrate re-organization of retinal lamination and loss of photoreceptors and epiretinal membrane in the left eye.
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activity
Two novel mutations in RDH12 were identiﬁed in
patients aﬀected with severe LCA (homozygote C201R
(patient 2) and compound heterozygote T49M/
A269fsX270 (patient 1)). These two mutations completely
abrogate Rdh12 enzymatic activity based on our in vitro
experiments which correlates with the severe phenotype.
Both patients are legally blind from early onset photore-
ceptor degeneration. The dramatic loss of all-trans-RDH
function of the C201R change at the catalytic motif corre-
lates with the severe retinal degeneration that characterizes
LCA. The T49M mutation was identiﬁed previously
(Janecke et al., 2004) in a patient diagnosed with juvenile
RP at 5 years old. This patient also carries 146C! T
resulting in R62X, which must result in a loss of function
mutation. Activity analysis performed by Thompson
et al. (2005) suggested that the T49M led to a two-fold
increase in Rdh12 activity, which we were not able to con-
ﬁrm in our study. Thus, the single enzyme activity of the
T49M mutation clearly showed much less all-trans-RDH
activity in this study. Similarly, our patient with the
146C! T mutation simultaneously carries 806delCCCTG
variant resulting in A269fsX270 which has no all-trans-
RDH activity in biochemical analysis. Both of the patients
showed severe loss of retinal function with an advanced ret-
inal dystrophy.
4.3. Role and clinical considerations related to LCA patients
with mutations in the RDH12 gene: Animal model study and
human physiology
Animal models lacking functional enzymes of the reti-
noid cycle exhibit varying forms of retinal degeneration
and the diﬀerences observed in Rdh12, Rpe65, and Lrat null
mice are apparent. All three proteins belong to the same
group of retinoid cycle molecules involved in the regenera-
tion of 11-cis-retinal; however, pathogenesis of retinal
degeneration is diﬀerent for all of the cases. In contrast
to Rpe65-/- mice and Lrat-/- mice, which appear to develop
retinal degeneration due to lack of 11-cis-retinal produc-
tion and their retinal structure remains well organized at
younger age, Rdh12-/- mice display unaﬀected 11-cis-reti-
nal synthesis (Batten et al., 2005; Imanishi, Batten, Piston,
Baehr, & Palczewski, 2004; Redmond et al., 1998). Gene
therapy and pharmacological bypass with artiﬁcial retinoid
chromophores were successful approaches in the rescue of
photoreceptors in Rpe65-/- mice and Lrat-/- mice (Acland
et al., 2005, 2001; Aleman et al., 2004; Batten et al., 2005;
Jacobson et al., 2005; Van Hooser et al., 2000; Van Hooser
et al., 2002) (reviewed in ref. (Travis, Golczak, Moise, &
Palczewski, 2007)). Rdh12 null mice exhibit normal retinal
structure at six weeks of age; however, they are highly sus-
ceptible to light induced retinal cell apoptosis in both cone
and rod photoreceptors (Maeda et al., 2006), thereby light
damage after birth can greatly contribute to severe retinaldegeneration also in humans. The retinal structure
observed for patient 2 with the RDH12 loss function muta-
tion showed poor organization, especially in the foveal
region which is exposed to the highest intensities of light.
Avoiding exposure to intense light, suppression of the
apoptotic pathway and slowing the retinoid cycle can all
be candidate approaches for the prevention of retinal
degeneration in patients with RDH12 mutations.
5. Conclusions
Mutations in RDH12 play a role in a broad range of
phenotypes that include patients aﬀected with LCA, RP,
and CORD. Of the six changes identiﬁed, three mutations
were novel. Our screening determined that the R160Q,
A177V mutations are polymorphic variants. Genotype–
phenotype correlation used biochemical studies and the
assessment of retinal structure and function. Biochemical
activity of Rdh12 mutant proteins associated with the
LCA phenotype was severely impaired, whereas those
mutants that are likely polymorphisms were fully active.
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